Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tango Therapeutics (TNGX) Shares Outstanding (2020 - 2025)

Tango Therapeutics has reported Shares Outstanding over the past 6 years, most recently at $135.9 million for Q4 2025.

  • Quarterly results put Shares Outstanding at $135.9 million for Q4 2025, up 26.19% from a year ago — trailing twelve months through Dec 2025 was $135.9 million (up 26.19% YoY), and the annual figure for FY2025 was $135.9 million, up 26.19%.
  • Shares Outstanding for Q4 2025 was $135.9 million at Tango Therapeutics, up from $111.6 million in the prior quarter.
  • Over the last five years, Shares Outstanding for TNGX hit a ceiling of $135.9 million in Q4 2025 and a floor of $48.4 million in Q1 2021.
  • Median Shares Outstanding over the past 5 years was $95.2 million (2023), compared with a mean of $95.0 million.
  • Biggest five-year swings in Shares Outstanding: soared 116.98% in 2021 and later grew 0.53% in 2023.
  • Tango Therapeutics' Shares Outstanding stood at $87.6 million in 2021, then grew by 0.66% to $88.2 million in 2022, then rose by 15.9% to $102.2 million in 2023, then rose by 5.41% to $107.7 million in 2024, then grew by 26.19% to $135.9 million in 2025.
  • The last three reported values for Shares Outstanding were $135.9 million (Q4 2025), $111.6 million (Q3 2025), and $110.9 million (Q2 2025) per Business Quant data.